Eisai China enters repackaging and sales deal for Stada's Alpha-Lipon 300
The Chinese unit of Japanese drugmaker Eisai has entered into license agreement with Health Vision Enterprise, a sales subsidiary of Germany's STADA Arzneimittel AG, for sales and repackaging of diabetic neuropathic pain treatment Alpha-Lipon 300 STADA (alpha-lipoic acid) in China. With this agreement, Eisai will take over sales promotion activities for the product from the Hong Kong-headquartered unit and will prepare for filing an application for repacking the product at its Suzhou plant. Alpha-Lipon 300 has been on the market in China since 2005. It relieves neuropathic pain associated with diabetes by its antioxidant effect, which reduces overproduction of oxygen species and normalization of glucose metabolism, the firms noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze